Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2025 · 40 (1)
DOI: 10.1080/14756366.2025.2481392 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 02.04.2025. Verfasst von Die Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Yan'an University, Yan'an City, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shaanxi Province, Yan’an Science and Technology Bureau, Yan’ an Science and Technology Bureau.
Abstract (Originalsprache)
Overactivation of the epidermal growth factor receptor (EGFR) is prevalent in various tumours, rendering it a promising target for cancer therapy, particularly in the treatment of non-small cell lung cancer (NSCLC). Although the first through third generations of EGFR tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy, the emergence of drug resistance continues to pose a challenge. Current research is now focused on fourth-generation EGFR-TKIs, which specifically target the EGFR harbouring the C797S mutation. This review examines the design strategies, antitumor activity both in vivo and in vitro, binding modes, pharmacokinetics, as well as the advantages and disadvantages of each inhibitor, alongside the progress of clinical stage research related to fourth-generation inhibitors. Additionally, the review discusses future development directions for fourth-generation EGFR-TKIs, aiming to provide insights for successful research and development in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Yan'an University, Yan'an City, China.
Förderung
- Natural Science Foundation of Shaanxi Province
- Yan’an Science and Technology Bureau
- Yan’ an Science and Technology Bureau
Zitieren
APA
Zhang, D., Zhao, J., Yang, Y., Dai, Q., Zhang, N., Mi, Z., Hu, Q., & Liu, X. (2025). Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future. Journal of Enzyme Inhibition and Medicinal Chemistry, 40(1). https://doi.org/10.1080/14756366.2025.2481392
Vancouver
Zhang D, Zhao J, Yang Y, Dai Q, Zhang N, Mi Z, et al. Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future. Journal of Enzyme Inhibition and Medicinal Chemistry. 2025;40(1). doi:10.1080/14756366.2025.2481392
BibTeX
@article{Zhang2025,
author = {Zhang, Die and Zhao, Jumei and Yang, Yue and Dai, Qiangfang and Zhang, Ning and Mi, Zhikuan and Hu, Qianqian and Liu, Xiaolong},
title = {Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2025},
volume = {40},
number = {1},
doi = {10.1080/14756366.2025.2481392}
}
EUVIMED